FCB Health Network president & CEO Dana Maiman announced that George Musi joined Solve(d) — the Network’s data and media company born from creative agency DNA — as managing director.

The World Health Organization said on June 1 it has approved a Covid-19 vaccine made by drugmaker Sinovac Biotech for emergency use listing, paving the way for a second Chinese shot to be used in poor countries.

Moderna Inc. on June 1 filed for full U.S. approval of the company’s Covid-19 vaccine, becoming the second drugmaker to do so after Pfizer Inc. and its German partner BioNTech SE sought full clearance for their vaccine in May.

India reported on May 29 that there were 173,790 new coronavirus infections during the previous 24 hours, the country’s lowest daily rise in 45 days, while deaths rose by 3,617.

A study out of Washington University School of Medicine in St. Louis found that months after recovering from mild Covid-19, patients maintained antibodies against the SARS-CoV-2 virus. Researchers believe that the specific cells that produce the antibodies should persist for a lifetime.

Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.  

Two Covid-19 vaccines from China’s Sinopharm showed more than 70 percent efficacy against symptomatic cases, but it remains unclear how much protection they provide against severe or asymptomatic cases, according to the first detailed result of a large late-stage study published to the public.

CytoReason and Ferring Pharmaceuticals announced a collaboration that pairs CytoReason’s artificial intelligence (AI)-based computational model of the human body with Ferring’s expertise in inflammatory bowel disease (IBD). The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.

Takeda has touted the potential of the company’s Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.

Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.